Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by TraderBuyon May 01, 2019 9:41pm

125 Views

Post# 29698354

KLY..Good direction..

The change from a net loss in 2017 to net income in 2018 is primarily due to a gain of approximately $14.2-million recorded in 2018 in connection with updated valuations of the company's outstanding derivative securities, as well as income of approximately $12.9-million related to the an update of the fair-value of contingent liabilities that relate to the company's acquisition of Talent Biotechs Ltd. in 2017.

Bullboard Posts

AI companies to invest in